Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SER-252 (PEOZ-apomorphine)
SER-252 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| SER-252 (PEOZ-apomorphine) | DRUG | SER-252 drug product consists of 20mg lyophilized apomorphine equivalent in SER-252 drug substance in a sterile vial for reconstitution with a diluent product containing 15mM acetate buffer at pH 6.0 and 7% trehalose to maintain final pH and isotonicity in the reconstituted product. |
| enFuse | DEVICE | The enFuse® device is a sterile, non-pyrogenic, user-filled, single-use, fixed-dose subcutaneous dose delivery system. |
SER-252 is an investigational small molecule therapeutic being developed by Serina Therapeutics, Inc. for Parkinson disease. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in patients with advanced Parkinson disease who experience motor fluctuations.
SER-252 is being developed for the treatment of Parkinson disease, specifically in patients with advanced disease and motor fluctuations. It is an investigational therapy and is not yet approved for any indication. Its use is currently limited to clinical trial evaluation.
SER-252 is being developed by Serina Therapeutics, Inc., a biopharmaceutical company. The company's ticker symbol is SER. Serina Therapeutics is responsible for the clinical development of SER-252.
SER-252 is in Phase 1 clinical development. A single Phase 1 trial is currently recruiting participants. The drug has not completed any trials and is not FDA approved. It remains an investigational therapy.
SER-252 is being evaluated in one active clinical trial: NCT07422675, a Phase 1 study titled SAD Study in Patients With Parkinson's Disease and Motor Fluctuations. The trial is currently recruiting and plans to enroll 40 participants. It is an uncontrolled study.
Yes, SER-252 is also known as PEOZ-apomorphine. Both names refer to the same investigational drug candidate being developed by Serina Therapeutics for Parkinson disease. The alternative name reflects its formulation with PEOZ technology.